financial results

GAM reported CHF 74.2M net loss in FY2025, improved from prior year, but assets fell to CHF 12.5B amid CHF 3.7B outflows.

Partners Value Investments cuts net losses 63% to $1.4B in 2025 as remeasurement gains improve, though adjusted earnings decline 46% amid currency headwinds.

Millicom announces 2026 AGM, proposes $3 dividend and 10% buyback authorization backed by $1.2B profit.

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

The Portnoy Law Firm investigates $TROY after 25% stock collapse triggered by disappointing Q2 earnings and major profit decline.

Byrna Technologies will report fiscal Q1 2026 financial results on April 9, 2026 at 9:00 a.m. ET via conference call with management Q&A.

SES AI faces securities investigation after stock plunged 36.8% following March 4 earnings, allegedly due to undisclosed $1.5M shipment delays.

CRMT shares plummeted 18.2% after reporting Q1 loss of 69 cents per share versus 15 cents prior year. Securities lawsuit investigation underway.

Maxim Power's 2025 net income fell to $16.7M from $21.9M, while securing GE turbine for Prairie Lights expansion with planned 2026 spending.

BioCardia scheduled conference call for March 24, 2026 to report full-year 2025 financial results and provide corporate update.

Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.

$BLNK to report Q4 2025 results and full-year financials on March 26, 2026, with investor conference call at 4:30 p.m. ET.

Oddity Tech shares crashed 49% after disclosing algorithm changes from its largest ad partner will trigger 30% Q1 revenue decline, prompting securities fraud investigation.

Tejon Ranch reported 7% revenue growth to $58.7M in 2025, though net income fell 96% to $0.1M due to $3.4M proxy defense costs.

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.